Receives U.S. FDA Approval to Expand the Use of RYALTRIS - Glenmark Pharmaceuticals Ltd

Code BSE: 532296 NSE: $GLENMARK Glenmark today announced that U.S. FDA has approved the expanded use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.